Leadership Overview
Alexion has 5 executives leading key functions including strategy, operations, revenue, and market development.
Driven by a commitment to patient well-being, Alexion focuses on developing transformative medicines for rare and devastating diseases, aiming to redefine treatment paradigms and improve lives globally.
Driven by a commitment to patient well-being, Alexion focuses on developing transformative medicines for rare and devastating diseases, aiming to redefine treatment paradigms and improve lives globally.
Leadership Roles at Alexion
Patrice Coissac - President
Patrice Coissac, the President at Alexion, provides overarching leadership and strategic direction for the company's global operations. Coissac guides the executive team in executing Alexion's mission to discover, develop, and deliver innovative medicines for individuals affected by severe and life-threatening rare diseases. This executive role involves setting the strategic vision, fostering a culture of scientific excellence and patient-centricity, and ensuring robust financial performance. Overseeing all major business functions, Patrice Coissac drives initiatives that enhance Alexion's market leadership and expand its therapeutic reach. The President's leadership is pivotal in navigating the complexities of the biopharmaceutical industry and advancing the company's commitment to transforming the lives of patients worldwide through groundbreaking scientific advancements.
Mackenzie Halter - Operations Senior Director, Strategy & Chief of Staff To, Regulatory & Safety Head of Development
Mackenzie Halter, the Operations Senior Director, Strategy & Chief of Staff To, Regulatory & Safety Head of Development at Alexion, directs strategic initiatives and operational execution within critical development functions. Overseeing the integration of strategic planning with day-to-day operations, Halter ensures seamless alignment between development timelines and regulatory compliance. This leadership role involves managing cross-functional projects that enhance efficiency and accelerate the delivery of life-changing therapies for rare disorders. By optimizing resource allocation and streamlining processes, Mackenzie Halter supports the company's mission to bring innovative treatments to patients worldwide. The focus remains on driving operational excellence and fostering a culture of continuous improvement across the development pipeline, directly impacting Alexion's ability to address unmet medical needs.
Moh-Lim Ong - Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer
Moh-Lim Ong, the Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer at Alexion, spearheads integrated business planning and operational strategies for the medical office while also driving marketing initiatives. This dual focus ensures that medical insights inform commercial strategies and that operational frameworks support both functions effectively. Ong oversees the development and execution of comprehensive business plans, optimizing resource deployment to maximize impact. The Chief Marketing Officer responsibilities involve shaping Alexion's market presence and communicating the value of its specialized therapies to healthcare providers and patient communities. By bridging the gap between medical affairs and marketing, Moh-Lim Ong enhances the company's ability to reach and serve individuals affected by rare diseases, reinforcing Alexion's commitment to patient access and therapeutic innovation.
Sean Gorman - Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer
Sean Gorman, the Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer at Alexion, manages critical business planning and operational functions for the medical office, concurrently leading marketing efforts. Gorman's role integrates strategic operational oversight with the development and implementation of targeted marketing campaigns. This involves ensuring that business planning directly supports the medical office's objectives and that marketing strategies effectively communicate Alexion's therapeutic advancements. Overseeing operational efficiency, Gorman ensures that resources are allocated optimally to support both internal medical operations and external market engagement. As Chief Marketing Officer, Sean Gorman drives initiatives to expand awareness and adoption of Alexion's treatments for rare disorders, thereby advancing the company's mission to serve patient populations with significant unmet needs.
Yi Su - Chief Revenue Officer & Manager
Yi Su, the Chief Revenue Officer & Manager at Alexion, directs all revenue-generating activities and manages key business operations critical to financial growth. Su oversees the strategic planning and execution of sales initiatives, aiming to maximize market penetration and revenue streams for Alexion's portfolio of rare disease therapies. This leadership position involves close collaboration with commercial, medical, and operational teams to ensure cohesive strategies that drive sustainable revenue growth. The managerial aspect of the role ensures operational efficiency supports these revenue objectives. By focusing on market dynamics and customer needs, Yi Su works to expand access to Alexion's life-changing medicines, directly contributing to the company's financial health and its ability to invest in further research and development for severe, rare disorders.
Explore Leadership Teams in Manufacturing
Founded in 1885, Boehringer Ingelheim is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products.
Company Leadership EM
RP
YL
Dexcel Pharma is Israel’s largest privately owned pharmaceutical company, founded in 1968 and headquartered in Or Akiva. It develops, manufactures, and commercializes value‑added branded prescription drugs, generics, and OTC products—primarily oral solid dosage forms—supplying more than 85 products in over 175 dosage forms to markets including the U.S., U.K., Germany, Austria, and others through subsidiaries and distribution partners.
Company Leadership
UE
EH
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
AskBio, is a fully integrated molecular medicine and technology company with operations around the globe. AskBio remains dedicated to the advancement of transformative gene therapeutics, pioneering research and development, groundbreaking synthetic biology, and scalable cGMP manufacturing. Its robust pipeline includes gene therapy candidates at various clinical stages for neuromuscular, central nervous system, metabolic, and cardiovascular diseases. AskBio also has a portfolio of over 775 molecular and genetic medicine patents and an expansive library of capsids and promoters. Global headquarters are in RTP, NC, and European headquarters in Edinburgh. AskBios AAV research centers are in Philadelphia, PA; Columbus, OH; and Paris. Modern clinical, commercial, and synthetic DNA manufacturing facilities are in San Sebastian, Spain. AskBio is a wholly owned, independently operated subsidiary of Bayer.
Company Leadership
CC
JK
Frequently Asked Questions Regarding Alexion Top Executives and Leadership Team
